do not combine dpp-4 inhibitors with glp-1 receptor agonists guidance Why are DPP-4 ( do not combine dpp-4 inhibitors

doi: 10.2147/OTT 72 Bjerre KnudsenLMadsenLWAndersenSAlmholtKde BoerASDruckerDJet al

Definitions of long-term weight regain and their associations with clinical outcomes

Observational Studies on GLP-1R Agonists and Substance Use Outcomes The clinical potential of GLP-1RAs in modulating substance use behaviors has been increasingly recognized through preclinical and early translational studies

Y., Nishida, T., Ogawa, W., Tobe, K., Yamauchi, T., & Lim, S

PLoS ONE 10 , e0130894 (2015)

Discussion at the American Heart Association session underscored the stakes of such decisions, as it was noted that an estimated 6.6 million American adults meet the inclusion criteria for the SELECT trial